ClinicalTrials.gg

Program

Alpha V Beta 8 Antagonist PF-06940434

In Pfizer’s pipeline, Integrin alpha-V/beta-8 antagonist. Its studies are mostly in Squamous Cell Carcinoma of Head and Neck, led by Pfizer.

Furthest: phase 1, since Oct 30, 20191 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer10 open or runningphase 1since Oct 30, 2019Oct 30, 2019none ahead
  • Named in Pfizer’s own pipeline as PF-06940434, phase 1, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 30, 2019First study: phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT04152018 · 85 enrolled · United States, Australia, Korea, Republic of and more

TargetBeta

“Integrin alpha-V/beta-8 antagonist”the company's pipeline, read by Claude · source
“An antagonist of integrin alpha v beta 8, with potential antineoplastic activity. Upon administration, PF-06940434 selectively binds to and blocks the receptor for integrin alpha v beta 8, thereby preventing integrin alpha v beta 8 binding. This may result in the inhibition of cell adhesion in th…”NCIt, read by Claude

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04152018Squamous Cell Carcinoma of Head and Neck · United States, Australia, Korea, Republic of and more1TerminatedDec 10, 202485

How it is read

Names in the registry

  • “PF-06940434”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.